I. Caroline Le Poole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
I. Caroline Le Poole has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Jared Klarquist
Departments of Pathology and Microbiology & Immunology/Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood (IL)
7 shared publicationsCecele J. Denman
Departments of Pathology, Microbiology and Immunology/Oncology Institute, Loyola University Chicago, Maywood, IL 60153, USA
6 shared publicationsClaudia Hernandez
Department of Dermatology University of Illinois at Chicago Chicago IL USA
6 shared publicationsRaymond E. Boissy
Department of Dermatology, University of Cincinnati, Cincinnati (OH)
5 shared publicationsHemamalini Bommiasamy
Department of Microbiology and Immunology, Loyola University Medical Center, Maywood, USA
4 shared publicationsJeffrey A. Mosenson
Departments of Pathology and Microbiology & Immunology/Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA
4 shared publications
Latest Publications
- 20 December 2013
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 27 (2) , 209-220
Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress
Summary: Inducible HSP70 (HSP70i) chaperones peptides from stressed cells, protecting them from apoptosis. Upon extracellular release, HSP70i serves an adjuvant function, enhancing immune responses to bound peptides. We questioned whether HSP70i differentially protects control and vitiligo melanocytes from stress and subsequent immune responses. We compared expression of HSP70i in skin samples, evaluated the viability of primary vitiligo and control melanocytes exposed to bleaching phenols, and measured secreted HSP70i. We determined whether HSP70i traffics to melanosomes to contact immunogenic proteins by cell fractionation, western blotting, electron microscopy, and confocal microscopy. Viability of vitiligo and control melanocytes was equally affected under stress. However, vitiligo melanocytes secreted increased amounts of HSP70i in response to MBEH, corroborating with aberrant HSP70i expression in patient skin. Intracellular HSP70i colocalized with melanosomes, and more so in response to MBEH in vitiligo melanocytes. Thus, whereas either agent is cytotoxic to melanocytes, MBEH preferentially induces immune responses to melanocytes.
- 20 December 2013
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 27 (2) , 209-220
Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress
Summary: Inducible HSP70 (HSP70i) chaperones peptides from stressed cells, protecting them from apoptosis. Upon extracellular release, HSP70i serves an adjuvant function, enhancing immune responses to bound peptides. We questioned whether HSP70i differentially protects control and vitiligo melanocytes from stress and subsequent immune responses. We compared expression of HSP70i in skin samples, evaluated the viability of primary vitiligo and control melanocytes exposed to bleaching phenols, and measured secreted HSP70i. We determined whether HSP70i traffics to melanosomes to contact immunogenic proteins by cell fractionation, western blotting, electron microscopy, and confocal microscopy. Viability of vitiligo and control melanocytes was equally affected under stress. However, vitiligo melanocytes secreted increased amounts of HSP70i in response to MBEH, corroborating with aberrant HSP70i expression in patient skin. Intracellular HSP70i colocalized with melanosomes, and more so in response to MBEH in vitiligo melanocytes. Thus, whereas either agent is cytotoxic to melanocytes, MBEH preferentially induces immune responses to melanocytes.
- Open Access
- 29 May 2013
- Published by Wiley in Experimental Dermatology
- Vol. 22 (9) , 566-569
A central role for inducible heat‐shock protein 70 in autoimmune vitiligo
Inducible heat‐shock protein 70 (HSP70i) is a protein regulated by stress that protects cells from undergoing apoptosis. Such proteins are marvellously well conserved throughout evolution, which has placed them in the spotlight for helping to understand the intriguing relationship between infection and immunity. In the presence of stress proteins, dendritic cells (DCs) will sense this alarm signal and respond by recruiting immune cells of different plumage to fit the occasion. In times of stress, melanocytes will secrete antigen‐bound HSP70i to act as an alarm signal in activating DCs that comes equipped with an address of origin to drive the autoimmune response in vitiligo. Here we pose that if the autoimmune response is funnelled through HSP70i, then blocking the stress protein from activating DCs can lend new treatment opportunities for vitiligo.
- 29 May 2013
- Published by Wiley in Experimental Dermatology
- Vol. 22 (9) , 566-569
Open AccessA central role for inducible heat‐shock protein 70 in autoimmune vitiligo
Inducible heat‐shock protein 70 (HSP70i) is a protein regulated by stress that protects cells from undergoing apoptosis. Such proteins are marvellously well conserved throughout evolution, which has placed them in the spotlight for helping to understand the intriguing relationship between infection and immunity. In the presence of stress proteins, dendritic cells (DCs) will sense this alarm signal and respond by recruiting immune cells of different plumage to fit the occasion. In times of stress, melanocytes will secrete antigen‐bound HSP70i to act as an alarm signal in activating DCs that comes equipped with an address of origin to drive the autoimmune response in vitiligo. Here we pose that if the autoimmune response is funnelled through HSP70i, then blocking the stress protein from activating DCs can lend new treatment opportunities for vitiligo.
- 27 February 2013
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 5 (174) , 174ra28
Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo
Vitiligo can be reversed through immune targeting with mutant heat shock protein 70.
- 27 February 2013
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 5 (174) , 174ra28
Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo
Vitiligo can be reversed through immune targeting with mutant heat shock protein 70.
- Open Access
- 6 October 2011
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 25 (1) , 88-98
HSP70i is a critical component of the immune response leading to vitiligo
Summary: HSP70i and other stress proteins have been used in anti‐tumor vaccines. This begs the question whether HSP70i plays a unique role in immune activation. We vaccinated inducible HSP70i (Hsp70‐1) knockout mice and wild‐type animals with optimized TRP‐1, a highly immunogenic melanosomal target molecule. We were unable to induce robust and lasting depigmentation in the Hsp70‐1 knockout mice, and in vivo cytolytic assays revealed a lack of cytotoxic T‐lymphocyte activity. Absence of T‐cell infiltration to the skin and maintenance of hair follicle melanocytes were observed. By contrast, depigmentation proceeded without interruption in mice lacking a tissue‐specific constitutive isoform of HSP70 (Hsp70‐2) vaccinated with TRP‐2. Next, we demonstrated that HSP70i was necessary and sufficient to accelerate depigmentation in vitiligo‐prone Pmel‐1 mice, accompanied by lasting phenotypic changes in dendritic cell subpopulations. In summary, these studies assign a unique function to HSP70i in vitiligo and identify HSP70i as a targetable entity for treatment.
- 6 October 2011
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 25 (1) , 88-98
Open AccessHSP70i is a critical component of the immune response leading to vitiligo
Summary: HSP70i and other stress proteins have been used in anti‐tumor vaccines. This begs the question whether HSP70i plays a unique role in immune activation. We vaccinated inducible HSP70i (Hsp70‐1) knockout mice and wild‐type animals with optimized TRP‐1, a highly immunogenic melanosomal target molecule. We were unable to induce robust and lasting depigmentation in the Hsp70‐1 knockout mice, and in vivo cytolytic assays revealed a lack of cytotoxic T‐lymphocyte activity. Absence of T‐cell infiltration to the skin and maintenance of hair follicle melanocytes were observed. By contrast, depigmentation proceeded without interruption in mice lacking a tissue‐specific constitutive isoform of HSP70 (Hsp70‐2) vaccinated with TRP‐2. Next, we demonstrated that HSP70i was necessary and sufficient to accelerate depigmentation in vitiligo‐prone Pmel‐1 mice, accompanied by lasting phenotypic changes in dendritic cell subpopulations. In summary, these studies assign a unique function to HSP70i in vitiligo and identify HSP70i as a targetable entity for treatment.
- 1 April 2011
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 21 (2) , 115-126
Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment
Skin depigmentation represents a well-established treatment for extensive vitiligo and may likewise be suited to prevent tumor recurrences and as a prophylactic treatment of familial melanoma, as common bleaching agents are cytotoxic to melanocytes. Effective melanoma prevention requires a bleaching agent-induced loss of exposed melanocytes supported by an immune response to distant pigment cells. Studies on human explant cultures treated with depigmenting agents such as 4-tertiary butyl phenol (4-TBP) or monobenzyl ether of hydroquinone (MBEH) showed a significant increase in the migration of Langerhans cells toward the dermis only upon treatment with MBEH, thus suggesting selective elicitation of an immune response. To assess the depigmenting potential of bleaching agents in vivo, 4-TBP and MBEH were topically applied to C57BL/6 wild type as well as k14-SCF transgenic, epidermally pigmented mice. MBEH-induced significant skin depigmentation in both strains was not observed upon treatment with 4-TBP. Cytokine expression patterns in skin treated with MBEH support activation of a Th1-mediated immune response corresponding to an influx of T cells and macrophages. Importantly, despite insensitivity of tumor cells to MBEH-induced cytotoxicity, significantly retarded tumor growth was observed in B16 challenged k14-SCF mice pretreated with MBEH, likely due to an abundance of cytotoxic T cells accompanied by an increased expression of Th1 and Th17 cytokines. These data support the use of MBEH as a prophylactic treatment for melanoma.
- 1 April 2011
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 21 (2) , 115-126
Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment
Skin depigmentation represents a well-established treatment for extensive vitiligo and may likewise be suited to prevent tumor recurrences and as a prophylactic treatment of familial melanoma, as common bleaching agents are cytotoxic to melanocytes. Effective melanoma prevention requires a bleaching agent-induced loss of exposed melanocytes supported by an immune response to distant pigment cells. Studies on human explant cultures treated with depigmenting agents such as 4-tertiary butyl phenol (4-TBP) or monobenzyl ether of hydroquinone (MBEH) showed a significant increase in the migration of Langerhans cells toward the dermis only upon treatment with MBEH, thus suggesting selective elicitation of an immune response. To assess the depigmenting potential of bleaching agents in vivo, 4-TBP and MBEH were topically applied to C57BL/6 wild type as well as k14-SCF transgenic, epidermally pigmented mice. MBEH-induced significant skin depigmentation in both strains was not observed upon treatment with 4-TBP. Cytokine expression patterns in skin treated with MBEH support activation of a Th1-mediated immune response corresponding to an influx of T cells and macrophages. Importantly, despite insensitivity of tumor cells to MBEH-induced cytotoxicity, significantly retarded tumor growth was observed in B16 challenged k14-SCF mice pretreated with MBEH, likely due to an abundance of cytotoxic T cells accompanied by an increased expression of Th1 and Th17 cytokines. These data support the use of MBEH as a prophylactic treatment for melanoma.
- 1 November 2010
- Published by Wolters Kluwer Health in Journal of the Dermatology Nurses' Association
- Vol. 2 (6) , 265-272
Vitiligo Etiology and Treatment
The disease pathway of the skin pigmentary disorder vitiligo involves hereditary factors, disease onset after overproduction of reactive oxygen species, and disease expansion through an adaptive, antigen-specific immune response to melanocytes. The current study was performed to obtain further knowledge of the disease process through patient questionnaires. Fifteen questions describing the condition of vitiligo were posted on the National Vitiligo Foundation and Vitiligo Support International Web sites and distributed by participating dermatologists to patients visiting their clinics. A total of 400 responses to the survey were collected and subjected to statistical analysis. The data support an overall increase in affected skin averaging 1% per year, with 50% of patients displaying a Koebner phenomenon, where new skin lesions appear at sites of trauma. Approximately 25% more women than men develop the disease. Patients recognize the importance of hereditary factors and the involvement of stress in precipitating the disease, yet only few note the contribution of an autoimmune response. Patients with relatives affected by vitiligo demonstrated an earlier age of onset. Autoimmune diseases found to be at least 25-fold more prevalent among respondents include Addison's disease, sarcoidosis, diabetes, and alopecia areata. Among a third of patients currently undergoing treatment, half note satisfactory efficacy, in particular for depigmentation treatment or topical immune modulation. The study has provided new insight into vitiligo disease parameters.
- 1 November 2010
- Published by Wolters Kluwer Health in Journal of the Dermatology Nurses' Association
- Vol. 2 (6) , 265-272
Vitiligo Etiology and Treatment
The disease pathway of the skin pigmentary disorder vitiligo involves hereditary factors, disease onset after overproduction of reactive oxygen species, and disease expansion through an adaptive, antigen-specific immune response to melanocytes. The current study was performed to obtain further knowledge of the disease process through patient questionnaires. Fifteen questions describing the condition of vitiligo were posted on the National Vitiligo Foundation and Vitiligo Support International Web sites and distributed by participating dermatologists to patients visiting their clinics. A total of 400 responses to the survey were collected and subjected to statistical analysis. The data support an overall increase in affected skin averaging 1% per year, with 50% of patients displaying a Koebner phenomenon, where new skin lesions appear at sites of trauma. Approximately 25% more women than men develop the disease. Patients recognize the importance of hereditary factors and the involvement of stress in precipitating the disease, yet only few note the contribution of an autoimmune response. Patients with relatives affected by vitiligo demonstrated an earlier age of onset. Autoimmune diseases found to be at least 25-fold more prevalent among respondents include Addison's disease, sarcoidosis, diabetes, and alopecia areata. Among a third of patients currently undergoing treatment, half note satisfactory efficacy, in particular for depigmentation treatment or topical immune modulation. The study has provided new insight into vitiligo disease parameters.
- Open Access
- 19 February 2010
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 23 (2) , 276-286
Reduced skin homing by functional Treg in vitiligo
In human vitiligo, cutaneous depigmentation involves cytotoxic activity of autoreactive T cells. It was hypothesized that depigmentation can progress in the absence of regulatory T cells (Treg). The percentage of Treg among skin infiltrating T cells was evaluated by immunoenzymatic double staining for CD3 and FoxP3, revealing drastically reduced numbers of Treg in non‐lesional, perilesional and lesional vitiligo skin. Assessment of the circulating Treg pool by FACS analysis of CD4, CD25, CD127 and FoxP3 expression, and mixed lymphocyte reactions in presence and absence of sorted Treg revealed no systemic drop in the abundance or activity of Treg in vitiligo patients. Expression of skin homing receptors CCR4, CCR5, CCR8 and CLA was comparable among circulating vitiligo and control Treg. Treg from either source were equally capable of migrating towards CCR4 ligand and skin homing chemokine CCL22, yet significantly reduced expression of CCL22 in vitiligo skin observed by immunohistochemistry may explain failure of circulating, functional Treg to home to the skin in vitiligo. The paucity of Treg in vitiligo skin is likely crucial for perpetual anti‐melanocyte reactivity in progressive disease.
- 19 February 2010
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 23 (2) , 276-286
Open AccessReduced skin homing by functional Treg in vitiligo
In human vitiligo, cutaneous depigmentation involves cytotoxic activity of autoreactive T cells. It was hypothesized that depigmentation can progress in the absence of regulatory T cells (Treg). The percentage of Treg among skin infiltrating T cells was evaluated by immunoenzymatic double staining for CD3 and FoxP3, revealing drastically reduced numbers of Treg in non‐lesional, perilesional and lesional vitiligo skin. Assessment of the circulating Treg pool by FACS analysis of CD4, CD25, CD127 and FoxP3 expression, and mixed lymphocyte reactions in presence and absence of sorted Treg revealed no systemic drop in the abundance or activity of Treg in vitiligo patients. Expression of skin homing receptors CCR4, CCR5, CCR8 and CLA was comparable among circulating vitiligo and control Treg. Treg from either source were equally capable of migrating towards CCR4 ligand and skin homing chemokine CCL22, yet significantly reduced expression of CCL22 in vitiligo skin observed by immunohistochemistry may explain failure of circulating, functional Treg to home to the skin in vitiligo. The paucity of Treg in vitiligo skin is likely crucial for perpetual anti‐melanocyte reactivity in progressive disease.
- 1 January 2010
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 130 (1) , 211-220
Monobenzyl Ether of Hydroquinone and 4-Tertiary Butyl Phenol Activate Markedly Different Physiological Responses in Melanocytes: Relevance to Skin Depigmentation
- 1 January 2010
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 130 (1) , 211-220
Monobenzyl Ether of Hydroquinone and 4-Tertiary Butyl Phenol Activate Markedly Different Physiological Responses in Melanocytes: Relevance to Skin Depigmentation
- Open Access
- 1 August 2008
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 128 (8) , 2041-2048
HSP70i Accelerates Depigmentation in a Mouse Model of Autoimmune Vitiligo
- 1 August 2008
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 128 (8) , 2041-2048
Open AccessHSP70i Accelerates Depigmentation in a Mouse Model of Autoimmune Vitiligo